Ross Moat
Fortuna: 581 963 $ al 31/05/2026
Fortuna: 581 963 $ al 31/05/2026
Ross Moat currently works at Kiniksa Pharmaceuticals Ltd. as Chief Commercial Officer & Senior Vice President since 2022.
Mr. Moat also works at Kiniksa Pharmaceuticals International Plc as Chief Operating Officer & Executive Vice President starting in 2026.
Former roles include General Manager at Synageva BioPharma Corp.
and VP-EMEA Marketing & Commercial Operations at Novartis Gene Therapies, Inc. from 2018 to 2019.
Education includes an undergraduate degree from Middlesex University.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
0,03 % | 09/04/2026 | 12.029 ( 0,03 % ) | 581 963 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops and delivers therapeutic medicines for patients suffering from cardiovascular diseases | Corporate Officer/Principal | 01/02/2021 |
| Empresas | Cargo | Fin |
|---|---|---|
| AVEXIS INC | Ventas & Marketing | 01/06/2019 |
| SYNAGEVA BIOPHARMA CORP | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Middlesex University
Middlesex University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Synageva BioPharma Corp.
Synageva BioPharma Corp. BiotechnologyHealth Technology Develops and manufactures biopharmaceutical products | Health Technology |
Novartis Gene Therapies, Inc.
Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Operates as a clinical-stage gene therapy company | Health Technology |
Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops and delivers therapeutic medicines for patients suffering from cardiovascular diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.